Myriad Venture Partners — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
DualEntry is an AI-native enterprise resource planning (ERP) platform designed to replace legacy accounting systems for mid-market to enterprise businesses.
AI & Machine LearningEnterprise SoftwareFintechSaaSNew York, US
Santiago Nestares(Co-founder & CEO)inBenedict Dohmen(Co-founder)in
Co-investorsContraryKhosla VenturesLightspeed Venture PartnersGV (Google Ventures)Carya Venture PartnersLudlow Ventures+9 more
Tessera Therapeutics develops Gene Writing, a genome engineering technology platform designed to make permanent alterations to the human genome for treating diseases.
BiotechDigital HealthMedical Devices
Co-investorsArtis VenturesFlagship PioneeringMarch Capital PartnersOMX VenturesSoftBank Vision FundSolari Capital+4 more
Tessera provides a multi-agent AI platform for enterprise system modernization, automating processes across ERP, CRM, HCM, and finance systems with governed execution.
AI & Machine LearningEnterprise SoftwareSaaS
Kabir Nagrecha(Chief Executive Officer)inMing Chang(Chief Operating Officer)inAnirudh Sriram(Chief Technology Officer)inPrakash Gupta(Chief Revenue Officer)in
Co-investorsAndreessen HorowitzFoundation CapitalOsage University PartnersOUP (Osage University Partners)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.